Categories: Texas News

Texas seeing largest number of cases of deadly fungus in the country

(NEXSTAR) – The number of Candida auris infections reported to the Centers of Disease Control and Prevention this year has nearly tripled in the past three and a half months as health care providers struggle to contain the drug-resistant and deadly fungus.

At the end of April, the CDC had recorded 1,052 Candida auris. By Aug. 9, the last week of available data, the total number of cases had grown to 2,809 cases across 21 states,

Sponsored
surpassing the number of cases we saw at this time last year.

Candida auris, also called C. auris, was first identified in the U.S. fewer than 10 years ago. Since then, the number of cases have increased every year. The CDC has considered the fungus “an urgent antimicrobial resistance threat” because it has developed ways to defeat the drugs that are designed to kill it.

In the past three months, Kansas, Kentucky, Mississippi and Tennessee recorded their first cases, joining 17 other states that were already tracking the fungus’ spread in 2025.

Of the roughly 2,800 cases reported so far this year, about a quarter (or 727 cases) were in Texas alone. Already 69 more cases than the state saw in all of 2024 combined.

Some of the biggest spread was in the Midwest, where cases in a handful of states more than doubled since April. Illinois reported 362 cases, Michigan reported 342, Ohio had 291 and Indiana had 164.

Candida auris can be hard or impossible to be treat because antifungal medications aren’t effective.

Sponsored

“If you get infected with this pathogen that’s resistant to any treatment, there’s no treatment we can give you to help combat it. You’re all on your own,” Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, told Nexstar.

People with a healthy immune system may be able to fight off infection on their own, but the fungus mainly spreads in health care settings, where people are sick and vulnerable.

The fungus can survive on surfaces, like countertops, doorknobs, or even people’s skin, for a long time before spreading to vulnerable patients. People with catheters, breathing tubes, feeding tubes and PICC lines are at the highest risk because the pathogen can enter the body through these types of devices.

A study published last month, which looked at patients with Candida auris primarily in Nevada and Florida, found more than half of patients required admission to the intensive care unit and more than one-third needed mechanical ventilation. More than half of patients, whose average age was between 60 and 64, also needed a blood transfusion.

In the past, the CDC estimated that “based on information from a limited number of patients, 30–60% of people with C. auris infections have died. However, many of these people had other serious illnesses that also increased their risk of death.”

rssfeeds-admin

Share
Published by
rssfeeds-admin

Recent Posts

Salisbury sails through town meeting with all items approved and discussion of highway department project

As soon as the polls closed at Salisbury Town Hall on Tuesday evening, residents streamed…

4 minutes ago

Alternative app store AltStore PAL is joining the fediverse

AltStore PAL, the alternative iOS app store available in the European Union and Japan, is…

20 minutes ago

Zootopia 2 Is Now Streaming on Disney+

Zootopia 2 was Disney's biggest movie in 2025 thanks to a monstrous worldwide box office…

33 minutes ago

Microsoft’s GDC 2026 Keynote Live Report: ‘Building for the Future With Xbox’

Microsoft is set to hold a keynote at the Game Developers Conference to shed light…

33 minutes ago

The Baseus 100W Multi-Port USB Charger Packs a Handy Digital Display for Just $30

From portable gaming handhelds to smartphones, our lives rely on portable, untethered electronics, and it…

33 minutes ago

Canva’s new editing tool adds layers to AI-generated designs

Canva introduced a new feature that separates flat image files and AI-generated visuals into layered,…

1 hour ago

This website uses cookies.